Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice

Cancer Research

Volumn 58, Issue 21, 1998, Pages 4947-4956

  Liu, Ming ^a   Bryant, Matthew S ^a   Chen, Jianping ^a   Lee, Suining ^a   Yaremko, Bohdan ^a   Lipari, Phil ^a   Malkowski, Michael ^a   Ferrari, Eric ^a   Nielsen, Loretta ^a   Prioli, Nicholas ^a   Dell, Janet ^a   Sinha, Dineshwar ^a   Syed, Jameel ^a   Korfmacher, Walter A ^a   Nomeir, Amin A ^a   Lin, C C ^a   Wang, Lynn ^a   Taveras, Arthur G ^a   Doll, Ronald J ^a   Njoroge, F George ^a   Mallams, Alan K ^a   Remiszewski, Stacy ^a   Catino, Joseph J ^a   Girijavallabhan, Viyyoor M ^a   Kirschmeier, Paul ^a   Bishop, W Robert ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [4 (8 CHLORO 3,10 DIBROMO 6,11 DIHYDRO 5H BENZO 5,6 CYCLOHEPTA [1,2 B] PYRIDIN 11 YL) 1 PIPERIDINYL] 2 OXOETHYL] 1 PIPERIDINE CARBOXAMIDE; CYCLOPHOSPHAMIDE; FLUOROURACIL; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE RAS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

3T3 CELLS; ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENES, RAS; HUMANS; MACACA FASCICULARIS; MALE; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PIPERIDINES; PYRIDINES; RATS; TRANSPLANTATION, HETEROLOGOUS;

EID: 14344254868     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Barbacid, M. Ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
2. Joneson, T., White, M. A., Wigler, M. H., and Bar-Sagi, D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of RAS. Science (Washington DC), 271: 810-811, 1996.
3. Lowy, D. R., and Willumsen, B. M. Function and regulation of Ras. Annu. Rev. Biochem., 62: 851-891, 1993.
4. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
5. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
6. Gibbs, J. B., Kohl, N. E., Koblan, K. S., Omer, C. A., Sepp-Lorenzino, L., Rosen, N., Anthony, N. J., Conner, M. W., deSolms, S. J., Williams, T. M., Graham, S. L., Hartman, G. D., and Oliff, A. Farnesyltransferase inhibitors and anti-Ras therapy. Breast Cancer Res. Treat., 38: 75-83, 1996.
7. Shirasawa, S., Furuse, M., Yokoyama, N., and Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science (Washington DC), 260: 85-88, 1993.
8. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci. USA, 87: 3042-3046, 1990.
9. Kato, K., Cox, A. D., Hisaka, M. M., Graham, S. M., Buss, J. E., and Der, C. J. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. USA, 89: 6403-6407, 1992.
10. Schaefer, W. R., Kim, R., Sterne, R., Thorner, J., Kim, S-H., and Rine, J. Genetic and pharmacological suppression of oncogenic mutations in RAS genes of yeast and humans. Science (Washington DC), 245: 379-385, 1989.
11. James, G. L., Goldstein, J. L., and Brown, M. S. Polylysine, and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
12. Zhang, F., Bond, R., Wang, L., Windsor, W., Kirschmeier, P., Carr, D., and Bishop, W. R. Characterization of H, K and N-Ras as in vitro substrates for isoprenyl protein transferases. J. Biol. Chem., 272: 10232-10239, 1997.
13. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Cantino, J. J., Bishop, W. R., and Pai, J-K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
14. Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., and Garcia, A. M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem., 272: 14093-14097, 1997.
15. Liu, M., Bryant, M. S., Chen, J., Lee, S., Yaremko, B., Li, Z., Dell, J., Lipari, P., Malkowski, M., Prioli, N., Rossman, R. R., Korfmacher, W. A., Nomeir, A. A., Lin, C-D., Mallams, A. K., Kirschmeier, P., Doll, R. J., Catino, J. J., Girijavallabhan, V. M., and Bishop, W. R. Effects of SCH 59228, and orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Cancer Chemother. Pharmacol., in press, 1998.
16. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E., DeSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J. B., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
17. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., DeSolms, S. J., Giuliani, E., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
18. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
19. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
20. Bishop, W. R., Bond, R., Petrin, J., Wang, L., Patton, R., Doll, R., Njoroge, G., Catino, J. J., Schwartz, J., Windsor, W., Syto, R., Schwartz, J., Carr, D., James, L., and Kirschmeier, P. Novel tricyclic inhibitors of farnesyl transferase. J. Biol. Chem., 270: 30611-30618, 1995.
21. Njoroge, F. G., Vibulbhan, B., Pinto, P., Bishop, W. R., Bryant, M. S., Nomeir, A. A., Lin, C-C., Liu, M., Doll, R. J., Girijavallabhan, V., and Ganguly, A. K. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity. J. Med. Chem., 41: 1561-1567, 1998.
22. Bryant, M. S., Korfmacher, W. A., Wang, S., Nardo, C., Nomeir, A. A., Lin, C-C. Pharmacokinetic screening for selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography-atmospheric pressure ionization tandem mass spectrometry. J. Chromatogr., 777: 61-66, 1997.
23. Bryant, M. S., Liu, M., Korfmacher, W. A., Nardo, C., Wang, S., Chen, K. J., Nomeir, A. A., Chen, P., Lee, S., Li, Z., Doll, R. J., and Lin, C-C. LC-APCI/MS/MS analysis of serum and tumor samples from mice treated with a potent antitumor compound (SCH 59228). Proc. 45th American Society for Mass Spectometry Conf. Mass Spectrom. Allied Topics, Palm Springs, CA, June 1-5, 1997.
24. Mallams, A. K., Njoroge, F. G., Doll, R. J., Snow, M. E., Kaminski, J. J., Rossman, R. R., Vibulbhan, B., Bishop, W. R., Kirschmeier, P., Liu, M., Bryant, M. S., Alvarez, C., Carr, D., James, L., King, I., Li, Z., Lin, C-C., Nardo, C., Petrin, J., Remiszewski, S. W., Taveras, A. G., Wang, S., Wong, J., Catino, J., Girijavallabhan, V., and Ganguly, A. K. Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of Ras farnesylation. Bioorg. Med. Chem. Lett., 5: 93-99, 1997.
25. Andres, A-C., Schonenberger, C-A., Groner, B., Hennighausen, L., LeMeur, M., and Gerlinger, P. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice. Proc. Natl. Acad. Sci. USA, 84: 1299-1303, 1987.
26. Nielsen, L. L., Discafani, C. M., Gurnani, M., and Tyler, R. D. Histopathology of salivary and mammary gland tumors in transgenic mice expressing a human Ha-ras oncogene. Cancer Res., 51: 3762-3767, 1991.
27. Nielsen, L. L., Gurnani, M., and Tyler, R. D. Evaluation of the wap-ras transgenic mouse as a model system for testing anticancer drugs. Cancer Res., 52: 3733-3738, 1992.
28. Nielsen, L. L., Gurnani, M., Catino, J. J., and Tyler, R. D. In wap-ras transgenic mice, tumor phenotype but not cyclophosphamide-sensitivity is affected by genetic background. Anticancer Res., 15: 385-392, 1995.
29. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bearss, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohl, N. E. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
30. Gratzner, H. G. Monoclonal antibody to 5-bromo and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science (Washington DC), 218: 474-475, 1982.
31. Kohl, N. E., Mosser, S. D., DeSolms, J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
32. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDowell, R. S., Crowley, C., Lucas, B., Levinson, A., and Marsters, J. C. Benzodiazepine peptomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
33. Garcia, A. M., Rowell, C., Ackermann, K., Kowalczyk, J. J., and Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem., 268: 18415-18418, 1993.
34. Vogt, A., Qian, Y., Blaskovich, M. A., Fossum, R. D., Hamilton, A. D., and Sebti, S. M. A non-peptide mimetic of Ras-CAAX: selective inhibition of farnesyltransferase and Ras processing. J. Biol. Chem., 270: 660-664, 1995.
35. Hunt, J. T., Lee, V. G., Leftheris, K., Seizinger, B., Carboni, J., Mabus, J., Ricca, C., Yan, N., and Manne, V. Potent cell active non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem., 39: 353-358, 1996.
36. Leftheris, K., Kline, T., Vite, G. D., Cho, Y. H., Bhide, R. S., Patel, D. V., Patel, M. M., Schmidt, R. J., Weller, H. N., Andahazy, M. L., Carboni, J. M., Gullo-Brown, J. L., Lee, F. Y. F., Ricca, C., Rose, W. C., Yan, N., Barbacid, M., Hunt, J. T., Meyers, C. A., Seizinger, B. R., Zahler, R., and Manne, V. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. J. Med. Chem., 39: 224-236, 1996.
37. Graham, S. L., deSolms, S. J., Giuliani, E. A., Kohl, N. E., Mosser, S. D., Oliff, A. I., Pompliano, D. L., Rands, E., Breslin, M. J., Deana, A. A., Garsky, V. M., Scholz, T. H., Gibbs, J. B., and Smith, R. L. Pseudopeptide inhibitors of Ras farnesyl-protein transferase. J. Med. Chem. 37: 725-732, 1994.
38. deSolms, S. J., Deana, A. A., Giuliani, E. A., Graham, S. L., Kohl, N. E., Molsser, S. D., Oliff, A. I., Pompliano, D. L., Rands, E., Scholz, T. H., Wiggins, J. M., Gibbs, J. B., and Smith, R. L. Pseudodipeptide inhibitor of protein farnesyltransferase. J. Med. Chem., 38: 3967-3971, 1995.
39. Singh, S. B., and Lingham, R. B. Farnesyl-protein transferase inhibitors in early development. Exp. Opin. Invest. Drugs, 5: 1589-1599, 1996.
40. Cox, A. D., Garcia, A. M., Westwick, J. K., Kowalczyk, J. J., Lewis, M. D., Brenner, D. A., and Der, C. J. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated, or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem. 269: 19203-19206, 1994.
41. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
42. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
43. Der, C. J., and Cox, A. D. Farnesyltransferase inhibitors and cancer treatment: targeting simply ras? Biochim. Biophys. Acta. Rev. Cancer, 1333: F51-F71, 1997.
44. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C. Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res., 57: 708-713, 1997.
45. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibbs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
46. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D-S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 95: 1369-1374, 1998.